SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (417)9/30/2002 10:51:04 PM
From: scaram(o)uche  Read Replies (2) of 1022
 
>> Rick, please can you be bit more specific, in plain language? <<

Proteins from mice and humans are highly homologous. As a human repertoire matures in a mouse, there is regular old negative selection for self-reactivity. You are, therefore, restricted to fishing for epitopes on human proteins which (1) look foreign to a mouse, and (2) are immunogenic. By "immunogenic", I mean that there not only needs to be a "B cell epitope", but also a determinant recognized as foreign by helper T cells from the MuMab mouse. For highly homolgous proteins, it's difficult to find the rare cell to fuse. Abgenix, IMO, has a leg up over Medarex there.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext